AbbVie Inc. (NYSE:ABBV) Declares Quarterly Dividend of $1.73

AbbVie Inc. (NYSE:ABBV - Get Free Report) declared a quarterly dividend on Thursday, September 10th. Stockholders of record on Thursday, October 15th will be given a dividend of 1.73 per share on Monday, November 16th. This represents a c) annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Thursday, October 15th.

• Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

AbbVie has raised its dividend by an average of 0.1%per year over the last three years and has raised its dividend every year for the last 53 years. AbbVie has a payout ratio of 49.5% indicating that its dividend is sufficiently covered by earnings. Analysts expect AbbVie to earn $16.15 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 42.8%.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $255.00 on Friday. The firm has a market cap of $450.52 billion, a price-to-earnings ratio of 72.03, a P/E/G ratio of 1.13 and a beta of 0.29. The firm has a fifty day moving average price of $254.54 and a 200 day moving average price of $230.76. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $267.47.

• MarketBeat Week in Review – 08/03 - 08/07

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the firm posted $2.97 EPS. AbbVie's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie will post 14.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Canaccord Genuity Group upped their price objective on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. JPMorgan Chase & Co. boosted their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an "overweight" rating in a research report on Thursday, July 9th. Royal Bank Of Canada upped their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, July 10th. Morgan Stanley reiterated an "overweight" rating and set a $296.00 price objective on shares of AbbVie in a research report on Monday, August 3rd. Finally, Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $276.64.

• The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure

Read Our Latest Research Report on AbbVie

AbbVie Company Profile

(Get Free Report)

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

Read More

• Five stocks we like better than AbbVie
• IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
• AeroVironment's Record Backlog and Earnings Beat Fuel Recovery Case
• Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
• 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here